𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia

✍ Scribed by Manfred Hensel; Martin Zoz; Christian Giesecke; Axel Benner; Kai Neben; Anna Jauch; Stephan Stilgenbauer; Anthony D. Ho; Alwin Krämer


Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
138 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

B‐cell chronic lymphocytic leukemia (CLL) is characterized by a high rate of clonal genomic alterations and a low proliferative activity with cell cycle arrest in G~0~/G~1~ phase. Recently, centrosome aberrations have been described as a possible cause of chromosomal instability and aneuploidy in many human malignancies. To investigate whether centrosome aberrations do occur in CLL and whether they correlate with common prognostic factors and disease activity, we examined peripheral blood mononuclear cells (PBMC) from 70 patients with previously untreated CLL using an antibody to γ‐tubulin. All 70 CLL samples displayed significantly more cells with centrosome aberrations (median: 26.0%, range 11.0–41.5%) as compared to peripheral blood B lymphocytes from 20 age‐matched, healthy individuals (median: 2.0%, range 0–6%; p < 0.001). The extent of centrosome aberrations correlated with the proliferative activity of the CLL cases as measured by lymphocyte doubling time (p = 0.02) as well as with time to first treatment (p = 0.05). Accordingly, more centrosome aberrations were found in PHA‐stimulated T lymphocytes from healthy individuals as well as in B cells from surgically removed tonsil tissue of patients with acute tonsillitis as compared to the peripheral blood B lymphocytes from the control group. In contrast, no correlation was observed between centrosome aberrations and immunoglobulin VH gene mutation status or cytogenetically defined risk groups. These findings suggest that, despite the common observation of most CLL cells remaining in G~0~/G~1~ phase, their centrosome replication process is deregulated and correlates to the proliferative activity of CLL cells. © 2007 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Thalidomide and dexamethasone therapy of
✍ James C. Barton 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 2 views

## Abstract A 67‐year‐old woman with previously untreated lambda‐positive B‐chronic lymphocytic leukemia (CLL) had kappa‐positive myeloma develop that was treated with daily thalidomide and intermittent dexamethasone. After 4 months, there was a marked reduction in marrow plasmacytosis, urine kappa

Routine clinical use of alemtuzumab in p
✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono